Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here's a look at what you need to know.

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...

Meanwhile, Novo had agreed supply deals with Hims and several of its bigger rivals. The idea was to give their existing ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...